Prevalence of atherosclerotic cardiovascular disease and subsequent major adverse cardiovascular events in Alberta, Canada: A real‐world evidence study

Abstract

Background: Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality worldwide. Data from Canadian populations regarding the burden of ASCVD are limited. Therefore, we describe the 5-year period prevalence of ASCVD and subsequent major adverse cardiovascular event (MACE) outcomes among patients with ASCVD in Alberta, Canada.Methods: A retrospective, observational study was conducted by linking provincial health services data, vital statistics, and pharmaceutical dispenses data. Five-year period prevalence of clinical ASCVD was captured between 2011 and 2016, and a cohort of adult patients with an initial clinical ASCVD event were identified between 2012 and 2016. One-year incidence rates (IRs) of subsequent MACE outcomes were calculated as composite and individual measures. A subgroup of patients with acute myocardial infarction (AMI) as their index event was examined.Results: There were 198 573 patients (mean [standard deviation] age: 63.9 [15.6] years; 56.6% males) identified with clinical ASCVD between 2012 and 2016. Overall, the 5-year period prevalence of ASCVD in Alberta was 89.9 per 1000 persons and the 1-year IR for a primary MACE outcome was 6.15 (95% confidence interval [CI]: 6.03-6.26) per 100 person-years. Among the ASCVD cohort, 9465 had an AMI as their index event and the IR for a primary MACE outcome was 14.30 (95% CI: 13.45-15.20) per 100 person-years.Conclusions: This study found that the prevalence of ASCVD and the rate of subsequent MACE outcomes 1 year following the initial ASCVD event are substantial, particularly among patients with an AMI. Secondary prevention strategies aimed at lowering this risk are needed for patients with ASCVD.

Risk Factors for Major Cardiovascular Events in Adult Sepsis Survivors: A Population-Based Cohort Study*

“…The study dates were chosen to optimize data completeness, including laboratory information, and to allow a minimum follow-up of 1 year for all patients (to December 2017). Preexisting cardiovascular disease was defined—using International Classification of Diseases and Related Health Problems, Tenth Revision, Canada (ICD-10-CA ) codes ( Table S2 , http://links.lww.com/CCM/H284)—as the presence of any of the following during a 5-year lookback period prior to the index sepsis hospitalization: coronary heart disease, stroke or transient ischemic attack, peripheral vascular disease, and congestive heart failure (32, 33). To maximize sensitivity while classifying prior cardiovascular disease, the presence of a single code during the lookback period was sufficient.…”

Guideline LDL-C Threshold Achievement in Acute Myocardial Infarction Patients: A Real-World Evidence Study Demonstrating the Impact of Treatment Intensification with PCSK9i

“…AMI was defined as the first inpatient hospitalization with the codes I21 or I22 from the International Patients with a PCSK9i prescription dispense before their AMI date were also excluded. The end of follow-up was the earliest of: [1] death, [2] leaving the province after the AMI date (deregistered from the Population Registry), or [3] the end of the study period (March 31, 2020).…”

Perivascular CLICK‐gelatin delivery of thrombospondin‐2 small interfering RNA decreases development of intimal hyperplasia after arterial injury

“…Atherosclerotic cardiovascular disease affects more than 18.3 million people in the United States, has an estimated global adult prevalence rate of 9.8%, and commonly manifests as peripheral arterial disease (PAD) or coronary artery disease (CAD) 1–3 . PAD can lead to limb threatening ischemia as disease severity worsens, resulting in lower extremity rest pain, non‐healing ulcers, gangrene, and ultimately limb loss unless a revascularization procedure is successfully performed 4,5 .…”